Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)

Key facts

Sponsor

Kaplan Medical Center

Principal Investigator

Amnon Zung, MD

Kaplan Medical Center, affiliated with the Hebrew University of Jerusalem, Israel

Intervention

Glycerol Phenylbutyrate 1100 MG/ML(drug)

Enrollment

6 enrolled

Eligibility

20 years · MALE

Timeline

2021 – 2022

Study locations (1)

• Pediatric Endocrinology Unit, Kapan Medical Center, Rehovot, Israel

Collaborators

Weizmann Institute of Science

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Allan-Herndon-Dudley syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06566066
  Register for Patients With Thyroid Hormone Resistance.
  Charite University, Berlin, Germany
• ACTIVE NOT RECRUITINGPHASE2NCT02396459
  Triac Trial II in MCT8 Deficiency Patients
  Rare Thyroid Therapeutics International AB

See all trials for Allan-Herndon-Dudley syndrome →